Home  »  Hot Stocks   »  Can BioLineRx Ltd. (BLRX) Remain Competitive?...

Can BioLineRx Ltd. (BLRX) Remain Competitive?

BioLineRx Ltd. (NASDAQ:BLRX) went down by -33.77% from its latest closing price compared to the recent 1-year high of $3.15. The company’s stock price has collected -37.80% of loss in the last five trading sessions.

Is It Worth Investing in BioLineRx Ltd. (NASDAQ :BLRX) Right Now?

Plus, the 36-month beta value for BLRX is at 1.80. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for BioLineRx Ltd. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $6.63, which is $9.73 above the current price. BLRX currently public float of 47.73M and currently shorts hold a 0.73% ratio of that float. Today, the average trading volume of BLRX was 140.54K shares.

BLRX’s Market Performance

BLRX stocks went down by -37.80% for the week, with a monthly drop of -39.64% and a quarterly performance of -21.54%, while its annual performance rate touched -61.80%. The volatility ratio for the week stands at 10.01% while the volatility levels for the past 30 days are set at 7.02% for BioLineRx Ltd. The simple moving average for the period of the last 20 days is -35.38% for BLRX stocks with a simple moving average of -37.40% for the last 200 days.

Analysts’ Opinion of BLRX

Many brokerage firms have already submitted their reports for BLRX stocks, with Maxim Group repeating the rating for BLRX by listing it as a “Buy.” The predicted price for BLRX in the upcoming period, according to Maxim Group is $3 based on the research report published on May 18th of the previous year 2017.

Rodman & Renshaw, on the other hand, stated in their research note that they expect to see BLRX reach a price target of $3. The rating they have provided for BLRX stocks is “Buy” according to the report published on February 13th, 2017.

Maxim Group gave a rating of “Hold” to BLRX, setting the target price at $1 in the report published on August 12th of the previous year.

BLRX Trading at -33.43% from the 50-Day Moving Average

After a stumble in the market that brought BLRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.62% of loss for the given period.

Volatility was left at 7.02%, however, over the last 30 days, the volatility rate increased by 10.01%, as shares sank -38.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.61% lower at present.

During the last 5 trading sessions, BLRX fell by -37.80%, which changed the moving average for the period of 200-days by -60.47% in comparison to the 20-day moving average, which settled at $1.5458. In addition, BioLineRx Ltd. saw -50.00% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for BLRX

The total capital return value is set at -49.74, while invested capital returns managed to touch -57.84.

Based on BioLineRx Ltd. (BLRX), the company’s capital structure generated 6.83 points at debt to equity in total, while total debt to capital is 6.39. Total debt to assets is 5.71, with long-term debt to equity ratio resting at 2.53. Finally, the long-term debt to capital ratio is 2.37.

The liquidity ratio also appears to be rather interesting for investors as it stands at 5.91.

Is Cadence Bank (CADE) a Keeper?

Cadence Bank (NYSE:CADE) went down by -0.52% from its latest closing price compared to the recent 1-year high of $34.24. The company’s stock price has